Granulomatosis with Microscopic Polyangiitis (MPA) Archives

FDA Approves Genentech’s Rituxan (rituximab) in Children With Two Rare Blood Vessel Disorders

Approvals, Blood Transfusions, FDA, Granulomatosis with Microscopic Polyangiitis (MPA), Granulomatosis with Polyangiitis (GPA), Microscopic Polyangiitis (MPA), Pediatrics, Rare Diseases, Vasculitis

The U.S. Food and Drug Administration approved Roche/Genentech’s Rituxan (rituximab), in combination with glucocorticoids, for the treatment of granulomatosis with polyangiitis and microscopic polyangiitis in pediatric patients 2 years of age and older.

September 27, 2019/by Business Wire